Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1009 Friday IPOs
BioCentury & Getty Images

Finance

Kronos’ post-IPO gains build on $1B+ postmoney valuation

Two other biotechs also rise in aftermarket as queue swells

Oct 9, 2020 | 10:10 PM GMT

Shares of Kronos climbed 42% in their first day of trading Friday, adding to a postmoney valuation that had already topped

Read the full 509 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE